{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Tenax Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"TENX"},"Address":{"label":"Address","value":"ONE COPLEY PARKWAY,SUITE 490, MORRISVILLE, North Carolina, 27560, United States"},"Phone":{"label":"Phone","value":"+1 919 855-2100"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com."},"CompanyUrl":{"label":"Company Url","value":"https://www.tenaxthera.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher T. Giordano","title":"President, Chief Executive Officer & Director"},{"name":"Doug Randall","title":"Executive VP-Commercial & Business Operations"},{"name":"Stuart Rich","title":"Chief Medical Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}